Dr. Mikael Dolsten, M.D., Ph.D.
Board Member
Rocket Pharmaceuticals, Inc. (RCKT)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Dr. Mikael Dolsten, M.D., Ph.D.
Dr. Mikael Dolsten, M.D., Ph.D. is recorded as Board Member at Rocket Pharmaceuticals, Inc. (RCKT). Rocket Pharmaceuticals, Inc. reported in an 8-K filed September 11, 2024 that Dr. Mikael Dolsten, M.D., Ph.D. was appointed Director, effective September 9, 2024.
“On September 5, 2024, the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-09-09–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Rocket Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Gaurav Shah CEO, Board Member
- Aaron Ondrey CFO
- Carlos Garcia-Parada CFO
- John Militello CFO
- Chris Stevens COO
- Christopher Stevens COO
- Martin Wilson General Counsel
- Joseph Manhede Chief Accounting Officer
- Carsten Boess Board Member
- David P. Southwell Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.